121 related articles for article (PubMed ID: 7759466)
1. Interferon inhibitor factor predicting success of plasmapheresis in patients with multiple sclerosis.
Medenica RD; Mukerjee S; Huschart T; Corbitt W
J Clin Apher; 1994; 9(4):216-21. PubMed ID: 7759466
[TBL] [Abstract][Full Text] [Related]
2. Plasmapheresis combined with interferon: an effective therapy for multiple sclerosis.
Medenica RD; Mukerjee S; Alonso K; Lazovic G; Huschart T
J Clin Apher; 1994; 9(4):222-7. PubMed ID: 7538999
[TBL] [Abstract][Full Text] [Related]
3. Increased levels of antiviral MxA protein in peripheral blood of patients with a chronic disease of unknown etiology.
Chieux V; Chehadeh W; Hautecoeur P; Harvey J; Wattré P; Hober D
J Med Virol; 2001 Oct; 65(2):301-8. PubMed ID: 11536237
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cell activity in patients with multiple sclerosis: interferon and plasmapheresis.
Uchida A; Maida EM; Lenzhofer R; Micksche M
Immunobiology; 1982 Feb; 160(5):392-402. PubMed ID: 6175561
[TBL] [Abstract][Full Text] [Related]
5. Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection.
Bálint E; Bakay M; Onody K; Farkas F; Horváth G; Tolvaj G; Dávid K; Horányi M; Béládi I
Acta Microbiol Immunol Hung; 2004; 51(3):359-69. PubMed ID: 15571075
[TBL] [Abstract][Full Text] [Related]
6. Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.
Kivisäkk P; Alm GV; Tian WZ; Matusevicius D; Fredrikson S; Link H
Mult Scler; 1997 Jun; 3(3):184-90. PubMed ID: 9310964
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.
Myhr KM; Riise T; Green Lilleås FE; Beiske TG; Celius EG; Edland A; Jensen D; Larsen JP; Nilsen R; Nortvedt MW; Smievoll AI; Vedeler C; Nyland HI
Neurology; 1999 Mar; 52(5):1049-56. PubMed ID: 10102427
[TBL] [Abstract][Full Text] [Related]
8. Intermittent interferonemia and interferon responses in multiple sclerosis.
Hertzog PJ; Wright A; Harris G; Linnane AW; Mackay IR
Clin Immunol Immunopathol; 1991 Jan; 58(1):18-32. PubMed ID: 1701372
[TBL] [Abstract][Full Text] [Related]
9. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta.
Brickelmaier M; Hochman PS; Baciu R; Chao B; Cuervo JH; Whitty A
J Immunol Methods; 1999 Jul; 227(1-2):121-35. PubMed ID: 10485260
[TBL] [Abstract][Full Text] [Related]
10. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies.
Bengtsson AA; Sturfelt G; Truedsson L; Blomberg J; Alm G; Vallin H; Rönnblom L
Lupus; 2000; 9(9):664-71. PubMed ID: 11199920
[TBL] [Abstract][Full Text] [Related]
11. Experience with use of plasmapheresis in chronic progressive multiple sclerosis: the pros.
Khatri BO
Neurology; 1988 Jul; 38(7 Suppl 2):50-2. PubMed ID: 3290715
[TBL] [Abstract][Full Text] [Related]
12. Plasmapheresis decreases neuroelectric blocking activity in multiple sclerosis.
Stefoski D; Schauf CL; McLeod BC; Haywood CP; Davis FA
Neurology; 1982 Aug; 32(8):904-7. PubMed ID: 7201588
[TBL] [Abstract][Full Text] [Related]
13. Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis.
Brod SA; Kerman RH; Nelson LD; Marshall GD; Henninger EM; Khan M; Jin R; Wolinsky JS
Mult Scler; 1997 Feb; 3(1):1-7. PubMed ID: 9160341
[TBL] [Abstract][Full Text] [Related]
14. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature.
Salk A; Stobaugh DJ; Deepak P; Ehrenpreis ED
Ann Pharmacother; 2013 Apr; 47(4):537-42. PubMed ID: 23535814
[TBL] [Abstract][Full Text] [Related]
15. Correlation between interferon production and clinical disease activity in patients with multiple sclerosis.
Dettke M; Scheidt P; Prange H; Kirchner H
J Clin Immunol; 1997 Jul; 17(4):293-300. PubMed ID: 9258768
[TBL] [Abstract][Full Text] [Related]
16. Abnormal protein patterns in multiple sclerosis.
Wu JY; Welch KM; Duncan CC
Neurochem Res; 1979 Dec; 4(6):811-20. PubMed ID: 545165
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiological changes of inflammatory syndrome in multiple sclerosis after instituting therapeutic plasmapheresis.
Vlaic S; Poalelungi V; Bălăeţ M; Purcărea VL; Bălăeţ C; Coculescu BI
J Med Life; 2017; 10(1):50-53. PubMed ID: 28255377
[TBL] [Abstract][Full Text] [Related]
18. Biologic effects of interferons: relevance to multiple sclerosis.
Rudick RA; Ransohoff RM
Mult Scler; 1995; 1 Suppl 1():S12-6. PubMed ID: 9345391
[TBL] [Abstract][Full Text] [Related]
19. Contrasting effects of alpha, beta, and gamma interferons on nonspecific suppressor function in multiple sclerosis.
Noronha A; Toscas A; Jensen MA
Ann Neurol; 1992 Jan; 31(1):103-6. PubMed ID: 1371908
[TBL] [Abstract][Full Text] [Related]
20. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs.
Khatri BO; McQuillen MP; Harrington GJ; Schmoll D; Hoffmann RG
Neurology; 1985 Mar; 35(3):312-9. PubMed ID: 3974889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
